Inhibikase Therapeutics Inc — Quarterly Financial Data (NASDAQ:IKT) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Dividends per share ————— — Dividend yield % ————— — Payout ratio % ————— —

Notizie

BofA Securities avvia copertura su Inhibikase con rating Buy

BofA Securities initiates coverage on Inhibikase stock with Buy rating

Jefferies riconferma il rating Buy su Inhibikase, citando un percorso FDA più rapido

Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path

H.C. Wainwright avvia copertura su Inhibikase con rating Buy

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating

Monday’s Insider Activity: Top Executives Trade Shares at Tech Giants

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Gap (NYSE:GAP), Elastic (NYSE:ESTC)

Inhibikase Therapeutics fissa il prezzo dell’offerta pubblica a 100 milioni di dollari

Inhibikase Therapeutics prices $100 million public offering

Il titolo di Inhibikase Therapeutics scende dopo l’annuncio di un’offerta pubblica

Inhibikase Therapeutics stock falls after announcing public offering